OP
NKTR icon

ORG Partners’s Nektar Therapeutics NKTR Stock Holding History

ORG Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$845 Hold
20
– – ﹤0.01% 1558
2025
Q3 		$1.14K Buy
+20
New +$662 ﹤0.01% 1383
2025
Q2 		– Hold
0
– – – 1410

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ORG Partners's NKTR Position: Q4 2025 in Review

ORG Partners held its Nektar Therapeutics (NKTR) position steady in Q4 2025 at 20 shares worth $845. The position accounts for ﹤0.01% of the portfolio, ranked #1558.

ORG Partners first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.14K in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • ORG Partners held 20 shares of Nektar Therapeutics worth $845 as of Q4 2025.
  • ORG Partners left its Nektar Therapeutics share count unchanged in Q4 2025.
  • Nektar Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1558 holding.
  • ORG Partners first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • ORG Partners's Nektar Therapeutics position peaked at $1.14K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.